Hinge Bio, a Burlingame, CA-based biotechnology company, raised $30M in Series A funding.
The round was led by Point72 with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital, among others.
The company intends to use the funds to support entry of its lead product candidate, HB2198, into a Phase 1 clinical trial in patients living with Systemic Lupus Erythematosus (“Lupus”) as well as development of additional therapeutics from its proprietary GEM-DIMER™ platform to treat diseases with high unmet need.
Led by Chief Executive Officer Barry Selick, Ph.D., Hinge Bio is a development-stage biotechnology company leveraging its proprietary GEM-DIMER™ platform to design and develop therapeutics leading to better treatment outcomes for patients living with autoimmune, inflammatory, and infectious disease, as well as cancer. The GEM-DIMER™ technology platform enables the creation of multivalent, multispecific antibody-based therapeutics that are designed to bind their targets cooperatively allowing for dramatically enhanced biological activity and functionality.
FinSMEs
15/01/2025